

Optiscan Imaging Ltd (ASX:OIL)

Enabling "Real-time Virtual Biopsy" for Human Cancer Screening and Surgical Margin Detection

Notice

This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 28 February 2020.

The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor may require in evaluating a possible investment in OIL or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act 2001 (Cth). No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. Neither OIL, nor any of its officers, employees, officers, agents, consultants or advisers are under any obligation to update any information subsequent to the issue of this presentation.

Future Performance

This presentation contains certain forward-looking statements and unaudited information including regarding the Company's future growth plans, strategies, products, operating performance, milestones, guidance, opinions, estimates, targets, goals, forecasts, earnings and financial position (Forward Looking Statements). The Forward Looking Statements, in this presentation are based on assumptions and contingencies which are subject to change without notice. Actual results and achievements could be significantly different from those expressed in or implied by this presentation. The Forward Looking Statements involve subjective judgements and assumptions as to future events which may or may not be correct and should not be relied upon as an indication or guarantee of future performance. No representation, warranty or assurance (express or implied) is given or made in relation to the achievement of any Forward Looking Statement by any person (includingOIL).

Subject to any continuing obligations under applicable law, OIL disclaims any obligation or undertaking to provide any updates or revisions to any Forward Looking Statement in this presentation to reflect any change in expectations in relation to any such Forward Looking Statement or any change in events, conditions or circumstances on which any such statement is based. Nothing in this presentation will create an implication that there has been no change in the affairs of OIL since the date of this presentation.

Past performance

The operating and historical financial information in this presentation not an indication of OIL's views on its future performance or condition. Actual results could differ materially from those referred to in this presentation. Past performance of OIL is not and cannot be relied upon as an indicator of (and provides no guidance as to) future performance.



Not an offer or financial product advice

This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirements for a disclosure document required under the Corporations Act. This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. This presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire securities and does not and will not form any part of any contract for acquisition of securities. Each recipient of this presentation should make its own enquiries and investigations regarding all information in this presentation (including, without limitation, the assumptions, uncertainties and contingencies which may affect the future operations of OIL and the impact that different future outcomes may have on OIL).

This presentation has been prepared without taking into account any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. An investment in OIL's shares is subject to known and unknown risks, some of which are beyond the control of OIL. OIL does not guarantee any particular rate of return or the performance of OIL.

Liability

Neither OIL nor any of its officers, employees, officers, agents, consultants or advisers owe any duty (whether in equity, in tort or otherwise) to any investor in connection with this presentation nor do they have any liability (including, without limitation, in negligence) for any loss or damage arising from or in connection with this presentation, except to the extent that such liability may not lawfully be excluded.

To the maximum extent permitted by law, you acknowledge and agree that by taking part in this presentation you will not bring or institute any legal proceedings in contract, in tort, for breach of statutory duty or otherwise against OIL or any of its officers, employees, officers, agents, consultants or advisers in respect of any information provided to it in or in connection with this presentation.

Corporate Snapshot

Board

Darren Lurie – Executive Chairman

B.LLB (Hons) and B.COM (Hons)

Former Group CFO and Head of Corporate Development for EduCo International (an investee company of Baring Private Equity Asia). Darren is a former chair and non-executive director of ASX listed Farm Pride Foods Ltd (ASX:FRM).

Dr Philip Currie – Non Executive Director

MBBS (Hons), FRACP, MBA

Dr Currie is a leading cardiologist with more than 35 years experience in medical research, clinical cardiology and business. He completed his cardiology fellowship at the prestigious Mayo Clinic, staff cardiologist at both Mayo Clinic and Cleveland Clinic and was the Director of Echocardiography at Michigan Heart and Vascular Institute.

Graeme Mutton – Non Executive Director

CPA

Graeme is a long-standing shareholder in Optiscan and has a deep understanding of Optiscan's technology and applications. He is a former manager of an accounting practice and successful business owner and operator.

Total Securities on Issue


- 477,778,800 Ordinary Shares
- 25,600,000 unlisted options

Market Capitalisation: ~\$13million @2.7c

OPTISCAN Introduction - Technology

Optiscan Technology


- Successful Development of hand-held Confocal Microscope for Medical and Research Imaging
- World-leading and Patent Protected Technology
- Real-time "Virtual Biopsy", visualisation of human living tissue
- Capture all Cancer Cells in Surgery and reduce cutting of surrounding Tissue ("Tumour Margin")
- Reduce Number of and More Targeted Biopsies
- 4mm Diameter Probe (4.7mm inc Sheath)
- Incorporated in Optiscan "InVivage" and Carl Zeiss Meditec "Convivo" devices



Optiscan's Future: Enabling "Real Time Virtual Biopsy"

InVivage[®] Optiscan's Clinical Device


- Screening, Early Cancer Diagnosis and Targeted Biopsies
- Tumour margin detection in Cancer Surgery
- Initial Target Application: Oral Cancer



1. Oral Cancer Foundation. https://oralcancerfoundation.org/

2. Pollaers, K., et al., The economic burden of oral squamous cell carcinoma in Australia. Journal of Oral Pathology & Medicine, 2019. 48(7): p. 588-594. doi: 10.1111/jop.12907. Epub 2019 Jun 27.

New InVivage® User Interface Designed for Doctors



Squamous epithelial cells and taste bud papillae in tongue (0.5mm x 0.5mm view)

OPTISCAN – FY2020 Progress

3 Oral Cancer Studies and Trials:

- Memorial Sloan Kettering Cancer Centre in New York ("MSK") (on-going)
- Melbourne Dental School in collaboration with Peter MacCallum Cancer Centre, Royal Melbourne Hospital, MSK and Australian Centre for Oral Oncology Research and Education (awaiting final ethics approval)
- Australian Centre for Oral Oncology Research and Education (on-going)

Met with US FDA and obtained feedback for proposed 510(k) submission to market in the US

 Preparing documentation and plans for required testing for US regulatory approval

OPTISCAN – Steps for US Approval to Market Device

United States Food and Drug Administration (FDA) 510(K) Submission	Pre-Submission meeting with FDA in the USA - Jan 2020	Completed
	Supplemental Q-Sub (Request for Feedback) document being prepared for FDA based on meeting feedback	Commenced
	Building of additional InVivage Systems for clinical trials and regulatory testing	Commenced
	Arranging and scheduling required Activities for 510(k) Submission:	
	Dosing study for use of topical fluorescein	
	Usability Studies	
	Electrical Safety and EMC Certification Testing	
	Biocompatibility and Reprocessing Testing of Sheath	
	Environment and Packaging Integrity Testing	

Breast Cancer - Most Common Cancer in Women



2.1 million new cases of breast cancer predicted in 2018 (globally)¹ 15% of all new cancer cases in the United States are breast cancer² There are 556 Breast Centers in the USA accredited by the US Commission on Cancer³

There are 145 hospitals in Australia performing breast cancer surgeries⁴

The number of breast cancer cases and defined cancer centres represent a large target market. 20-30% of lumpectomy patients currently require repeat surgery with current practice (histopathology analysis) often taking up to 3-4 days post initial surgery


1. GLOBOCAN 2018 estimates; uses Bray et al 2018 paper in CA: A Cancer Journal for Clinicians, page 398 2. American Cancer Society Estimated 2019 statistics 3. https://www.facs.org/search/cancer-programs 4. https://www.facs.org/search/cancer-programs

Optiscan - Breast Cancer Surgery

Intraoperative Assessment of Breast Cancer Surgical Margin


- **Goal:** Assist breast surgeons and pathologists to provide real-time cellular assessment of surgical margin.
- <u>Benefits</u>: Reduce risk of residual tumour, need for repeat surgery, patient emotional distress, costs for patients, hospitals, insurers and the taxpayer by reducing the number of repeat surgeries

MDPP Workshop in Feb 2020 with 6 Breast Surgeons and a Pathologist from 5 Leading Melbourne Hospitals. Strong interest to arrange Stage 3 of Breast Cancer Trial in Melbourne.



Creation of panoramas: developing a more macro view of the specimen assisting in the CLE and H&E correlation






ZEISS CONVIVO® – CARL ZEISS MEDITEC (CZM) COLLABORATION

297,000 Brain and CNS cancer cases p.a. worldwide

ZEISS CONVIVO®


- Target Application: Tumour margin detection in Brain Cancer surgery
- Current 2nd half FY20 orders of at least \$450k with ongoing discussions re further revenue opportunities
- Zeiss is an international leader in optics and optoelectronics with a ~€9.0billion market capitalisation



OPTISCAN Research Device: Development of New Applications

Working in collaboration with CSIRO and Monash and Michigan Universities for new applications in 3D Tissue Culture and Anterior Cruciate Ligament (ACL) imaging respectively

 3D tissue culture imaging application developed in collaboration with CSIRO



 Autofluorescence imaging in ACL microdamage research in collaboration with Monash and Michigan Universities. Image on the left is a normal ACL while image on the right shows ACL microdamage (collagen disorder)



Distributor Strategy for Research Markets in China and North America

- New multi-distributor model in China with appointment of exclusive distributor in Southern and Western China.
 - South and West China: Guangzhou Yunxing (Purple and Blue)
 - **East China:** Biotimes Technology Limited (Green)
 - North China: To be Advised
- Sale of FIVE2 (ViewnVivo) System in late 2019:
 - Chinese University Tender success directly attributable to new Chinese multi-distributor model.
- North America Distributor Strategy Under Review







- Optiscan Device developed for "Real-time Virtual Biopsy" for Human Cancer Screening and Surgery
 - Button control features for single-handed operation unique to InVivage

→ Jan 2020: 510(k) Pre-Submission Meeting with FDA for Oral Cancer

Preparing documentation and arranging testing required for FDA 510(k) submission

Medical Device Partnering Program Workshop in Feb 2020 with 6 Breast Surgeons and a Pathologist from 5 Leading Melbourne Hospitals. Strong interest to arrange Stage 3 of Breast Cancer Trial in Melbourne.

Commercialisation of Carl Zeiss CONVIVO progressing in United States and Europe

\$450k of orders for Carl Zeiss CONVIVO received for second half of FY2020 and on-going discussions re further Revenue opportunities in this half and beyond.